The objective of this project is to develop anti-bcr-abl ribozymes (RZ) that can be used to purge stem cells in vitro of Philadelphia chromosome (Ph) positive leukemia cells from patients with PH+ acute lymphoblastic leukemia (ALL), for use in the reconstitution of Ph- hematopoiesis after myeloablative radiochemotherapy. The goal of specific aim one is first to synthesize RZs against the p190bcrabl and p210bcrabl oncogenes that can effectively cleave the mRNA of these oncogenes in Ph+ ALL cell lines and freshly isolated ALL cells. The second goal of aim one is to develop optimal strategies for the delivery and expression of the RZs in target cells, including transfection of synthetically modified RZs via liposome vectors, and transduction of Adeno-associated viral (AAV) and retroviral constructs containing the RZ genes. The third goal is to optimize the expression of the RZ gene within the viral constructs by testing a variety of promoters to drive transcription. The kinetics of the catalytic reaction of RZ and its substrate will be manipulated by exploiting naturally occurring binding proteins. After these in vitro studies are completed, the safety and efficacy of the optimal vector system found will be tested in a murine bone marrow transplant model in which transgenic mice which express the human p 190bcrabl gene develop acute leukemia a adults, and can transplant the disease to normal syngeneic mice via bone marrow cells.
In specific aim two the pathogenic role of the bcr-abl oncogene in Ph+ALL will be explored by studying the impact of RZ-mediated inhibition of bcr-abl gene expression on a variety of parameters of cell growth including apoptosis.
In specific aim three we plan to utilize the anti-bcr-abl RZ technology for the therapy of Ph+ ALL in humans. Our approach will be to use ablative chemotherapy and G-CSF to mobilize and collect peripheral blood stem cells (PBSC) from patients with Ph+ ALL in first or subsequent CR, and to purge those PBSC by transfecting them with RZ in liposomes and/or transducing them with the AAV/RZ or retroviral/RZ constructs. This RZ purging approach in the context of autologous BMT could offer a potentially curative therapy for those patients with Ph+ ALL for whom allogeneic BMT is not an option.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA030206-14
Application #
3729934
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1995
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications